On November 4, 2021 Grey Wolf Therapeutics, a biotechnology company spearheading a new therapeutic approach to immuno-oncology driven by targeted neoantigen generation, reported that preclinical in vivo data on the company’s first-in-class inhibitors of ERAP1 will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Grey Wolf Therapeutics, NOV 4, 2021, View Source [SID1234594569]). Presented findings will highlight the ability of the company’s novel ERAP1 inhibitors to significantly increase the diversity of T cell receptors in the tumor, drive synergistic upregulation of translationally relevant immune markers that have been shown to correlate with patient response to checkpoint inhibition, and trigger significantly greater T cell infiltration into tumors in preclinical models. Additionally, the presentation will showcase significant tumor growth inhibition in syngeneic mouse tumor models following combination of ERAP1 inhibition with an anti-PD-1 antibody. The SITC (Free SITC Whitepaper) conference is being held November 10-14, 2021 in Washington, D.C., as well as virtually.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Grey Wolf Therapeutics’ first-of-its-kind immuno-oncology approach is centered on dramatically increasing the visibility of tumors to allow for their identification and destruction by the body’s immune system. This is achieved through targeted inhibition of the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), causing the generation and presentation of novel and potent neoantigens to the surface of tumor cells. The appearance of these neoantigens uncloaks the tumor cells, illuminating them for the immune system and setting in motion powerful, differentiated T cell responses against the tumor. Importantly, this unique approach is orthogonal to a broad range of other cancer therapy modalities, including, but not limited to, immunotherapy. The company is developing a portfolio of ERAP inhibitors that it believes represents the first ever application of direct neoantigen generation to the treatment of cancer. GRWD5769, the company’s lead ERAP1 inhibitor development candidate, is expected to enter the clinic in the second half of 2022.
Details of the company’s presentation at the 2021 SITC (Free SITC Whitepaper) conference are as follows:
Poster Presentation #553:
Title: First-in-Class Inhibitors of ERAP1 Alter the Immunopeptidome of Cancer, Driving a Differentiated T Cell Response Leading to Tumor Growth Inhibition
Presenting Author: Peter Joyce, Ph.D., Chief Executive Officer of Grey Wolf Therapeutics
Date/Time: Friday, November 12, 2021, 7:00 a.m. – 8:30 p.m. Eastern
Location: Poster Hall – Hall E
The poster will be available for download (upon request) here following the annual meeting.